Johnson & Johnson (ETR:JNJ)
Germany
· Delayed Price · Currency is EUR 136.02
+1.30 (0.96%)
Jun 13, 2025, 5:35 PM CET
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $21.89B USD in the quarter ending March 30, 2025, with 2.39% growth. This brings the company's revenue in the last twelve months to $89.33B, up 4.30% year-over-year. In the year 2024, Johnson & Johnson had annual revenue of $88.82B with 4.30% growth.
Revenue (ttm)
$89.33B
Revenue Growth
+4.30%
P/S Ratio
3.97
Revenue / Employee
$646.86K
Employees
138,100
Market Cap
327.00B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 29, 2019 | Pro | Pro | Pro |
| Dec 30, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Jan 1, 2017 | Pro | Pro | Pro |
| Jan 3, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.14B |
| Merck KGaA | 21.32B |
| Bayer Aktiengesellschaft | 46.58B |
| Fresenius SE & Co. KGaA | 22.13B |
| Fresenius Medical Care AG | 19.49B |
| Sartorius Aktiengesellschaft | 3.44B |
| Carl Zeiss Meditec AG | 2.17B |
| Fielmann Group AG | 2.33B |
Johnson & Johnson News
- 2 days ago - Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma - PRNewsWire
- 3 days ago - New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia - PRNewsWire
- 3 days ago - Johnson & Johnson (JNJ) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis - PRNewsWire
- 4 days ago - New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis - Benzinga
- 4 days ago - Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors - Wallstreet:Online
- 4 days ago - Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors - Business Wire
- 6 days ago - Rep. Gilbert Ray Cisneros Has Bought Up to $410K Worth Of Johnson & Johnson Stock: Here's What You Should Know - Benzinga